Tengion bioengineered bladder trial
This article was originally published in The Gray Sheet
Executive Summary
Firm initiates enrollment Jan. 5 in a 10-patient, Phase II clinical trial of its bioengineered bladder-shaped collagen scaffold to treat bladder malfunctions that can lead to kidney failure and incontinence. Physicians take healthy cells from the patient's bladder and send them to Tengion, where they are grown and attached to the biodegradable collagen scaffold. The product is then surgically implanted into the patient's own failing bladder (1"The Gray Sheet" April 10, 2006, p. 15)...
You may also be interested in...
First Bioengineered Bladders In Humans Show Positive Results
The concept of bioengineered organs as a practical clinical strategy began, last week, to take shape - the oval-like shape of a bladder
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.